Thomas Dubensky on How ADU-S100 Activates STING

Video

Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.

Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.

The live-attenuated, double-deleted Listeria mononcytogenes (LADD) technology developed by Aduro Biotech is used in pancreatic cancer as a platform to induce antigens against specific tumors, Dubensky explains. Through a research collaboration, it was found that the potency of the LADD platform is due to inducing interferon expression, which turned out to be STING dependent.

ADU-S100, a small molecule, was delivered in preclinical models of advanced tumors and was found to promote anti-tumor efficacy. However, by activating the STING pathway in the tumor microenviornment, the tumor-resident dendritic cells could present antigen, produce a T-cell response, and was found to be systemically active.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD